Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: Results from a multicenter, Phase Ib study

Andrea B. Apolo, Jeffrey R. Infante, Ani Balmanoukian, Manish R. Patel, Ding Wang, Karen Kelly, Anthony E. Mega, Carolyn D. Britten, Alain Ravaud, Alain C. Mita, Howard Safran, Thomas E. Stinchcombe, Marko Srdanov, Arnold B. Gelb, Michael Schlichting, Kevin Chin, James L. Gulley

Research output: Contribution to journalArticle

232 Citations (Scopus)

Abstract

Purpose: We assessed the safety and antitumor activity of avelumab, a fully human anti-programmed death-ligand 1 (PD-L1) IgG1 antibody, in patients with refractory metastatic urothelial carcinoma. Methods: In this phase Ib, multicenter, expansion cohort, patients with urothelial carcinoma progressing after platinum-based chemotherapy and unselected for PD-L1 expression received avelumab 10 mg/kg intravenously every 2 weeks. The primary objectives were safety and tolerability. Secondary objectives included confirmed objective response rate (Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1), progression-free survival, overall survival (OS), and PD-L1-associated clinical activity. PD-L1 positivity was defined as expression by immunohistochemistry on ≥ 5% of tumor cells. Results: Forty-four patients were treated with avelumab and followed for a median of 16.5 months (interquartile range, 15.8 to 16.7 months). The data cutoff was March 19, 2016. The most frequent treatment-related adverse events of any grade were fatigue/asthenia (31.8%), infusion-related reaction (20.5%), and nausea (11.4%). Grades 3 to 4 treatment-related adverse events occurred in three patients (6.8%) and included asthenia, AST elevation, creatine phosphokinase elevation, and decreased appetite. The confirmed objective response rate by independent central review was 18.2% (95% CI, 8.2% to 32.7%; five complete responses and three partial responses). The median duration of response was not reached (95% CI, 12.1 weeks to not estimable), and responses were ongoing in six patients (75.0%), including four of five complete responses. Seven of eight responding patients had PD-L1-positive tumors. The median progression-free survival was 11.6 weeks (95% CI, 6.1 to 17.4 weeks); the median OS was 13.7 months (95% CI, 8.5 months to not estimable), with a 12-month OS rate of 54.3% (95% CI, 37.9% to 68.1%). Conclusion: Avelumab was well tolerated and associated with durable responses and prolonged survival in patients with refractory metastatic UC.

Original languageEnglish (US)
Pages (from-to)2117-2124
Number of pages8
JournalJournal of Clinical Oncology
Volume35
Issue number19
DOIs
StatePublished - Jul 1 2017
Externally publishedYes

Fingerprint

Ligands
Carcinoma
Antibodies
Asthenia
Disease-Free Survival
Survival
Safety
Appetite
Creatine Kinase
avelumab
Platinum
Nausea
Fatigue
Neoplasms
Survival Rate
Immunoglobulin G
Immunohistochemistry
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma : Results from a multicenter, Phase Ib study. / Apolo, Andrea B.; Infante, Jeffrey R.; Balmanoukian, Ani; Patel, Manish R.; Wang, Ding; Kelly, Karen; Mega, Anthony E.; Britten, Carolyn D.; Ravaud, Alain; Mita, Alain C.; Safran, Howard; Stinchcombe, Thomas E.; Srdanov, Marko; Gelb, Arnold B.; Schlichting, Michael; Chin, Kevin; Gulley, James L.

In: Journal of Clinical Oncology, Vol. 35, No. 19, 01.07.2017, p. 2117-2124.

Research output: Contribution to journalArticle

Apolo, AB, Infante, JR, Balmanoukian, A, Patel, MR, Wang, D, Kelly, K, Mega, AE, Britten, CD, Ravaud, A, Mita, AC, Safran, H, Stinchcombe, TE, Srdanov, M, Gelb, AB, Schlichting, M, Chin, K & Gulley, JL 2017, 'Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: Results from a multicenter, Phase Ib study', Journal of Clinical Oncology, vol. 35, no. 19, pp. 2117-2124. https://doi.org/10.1200/JCO.2016.71.6795
Apolo, Andrea B. ; Infante, Jeffrey R. ; Balmanoukian, Ani ; Patel, Manish R. ; Wang, Ding ; Kelly, Karen ; Mega, Anthony E. ; Britten, Carolyn D. ; Ravaud, Alain ; Mita, Alain C. ; Safran, Howard ; Stinchcombe, Thomas E. ; Srdanov, Marko ; Gelb, Arnold B. ; Schlichting, Michael ; Chin, Kevin ; Gulley, James L. / Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma : Results from a multicenter, Phase Ib study. In: Journal of Clinical Oncology. 2017 ; Vol. 35, No. 19. pp. 2117-2124.
@article{f90a720e6cc348d0b218a6c12d2a89ac,
title = "Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: Results from a multicenter, Phase Ib study",
abstract = "Purpose: We assessed the safety and antitumor activity of avelumab, a fully human anti-programmed death-ligand 1 (PD-L1) IgG1 antibody, in patients with refractory metastatic urothelial carcinoma. Methods: In this phase Ib, multicenter, expansion cohort, patients with urothelial carcinoma progressing after platinum-based chemotherapy and unselected for PD-L1 expression received avelumab 10 mg/kg intravenously every 2 weeks. The primary objectives were safety and tolerability. Secondary objectives included confirmed objective response rate (Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1), progression-free survival, overall survival (OS), and PD-L1-associated clinical activity. PD-L1 positivity was defined as expression by immunohistochemistry on ≥ 5{\%} of tumor cells. Results: Forty-four patients were treated with avelumab and followed for a median of 16.5 months (interquartile range, 15.8 to 16.7 months). The data cutoff was March 19, 2016. The most frequent treatment-related adverse events of any grade were fatigue/asthenia (31.8{\%}), infusion-related reaction (20.5{\%}), and nausea (11.4{\%}). Grades 3 to 4 treatment-related adverse events occurred in three patients (6.8{\%}) and included asthenia, AST elevation, creatine phosphokinase elevation, and decreased appetite. The confirmed objective response rate by independent central review was 18.2{\%} (95{\%} CI, 8.2{\%} to 32.7{\%}; five complete responses and three partial responses). The median duration of response was not reached (95{\%} CI, 12.1 weeks to not estimable), and responses were ongoing in six patients (75.0{\%}), including four of five complete responses. Seven of eight responding patients had PD-L1-positive tumors. The median progression-free survival was 11.6 weeks (95{\%} CI, 6.1 to 17.4 weeks); the median OS was 13.7 months (95{\%} CI, 8.5 months to not estimable), with a 12-month OS rate of 54.3{\%} (95{\%} CI, 37.9{\%} to 68.1{\%}). Conclusion: Avelumab was well tolerated and associated with durable responses and prolonged survival in patients with refractory metastatic UC.",
author = "Apolo, {Andrea B.} and Infante, {Jeffrey R.} and Ani Balmanoukian and Patel, {Manish R.} and Ding Wang and Karen Kelly and Mega, {Anthony E.} and Britten, {Carolyn D.} and Alain Ravaud and Mita, {Alain C.} and Howard Safran and Stinchcombe, {Thomas E.} and Marko Srdanov and Gelb, {Arnold B.} and Michael Schlichting and Kevin Chin and Gulley, {James L.}",
year = "2017",
month = "7",
day = "1",
doi = "10.1200/JCO.2016.71.6795",
language = "English (US)",
volume = "35",
pages = "2117--2124",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "19",

}

TY - JOUR

T1 - Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma

T2 - Results from a multicenter, Phase Ib study

AU - Apolo, Andrea B.

AU - Infante, Jeffrey R.

AU - Balmanoukian, Ani

AU - Patel, Manish R.

AU - Wang, Ding

AU - Kelly, Karen

AU - Mega, Anthony E.

AU - Britten, Carolyn D.

AU - Ravaud, Alain

AU - Mita, Alain C.

AU - Safran, Howard

AU - Stinchcombe, Thomas E.

AU - Srdanov, Marko

AU - Gelb, Arnold B.

AU - Schlichting, Michael

AU - Chin, Kevin

AU - Gulley, James L.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Purpose: We assessed the safety and antitumor activity of avelumab, a fully human anti-programmed death-ligand 1 (PD-L1) IgG1 antibody, in patients with refractory metastatic urothelial carcinoma. Methods: In this phase Ib, multicenter, expansion cohort, patients with urothelial carcinoma progressing after platinum-based chemotherapy and unselected for PD-L1 expression received avelumab 10 mg/kg intravenously every 2 weeks. The primary objectives were safety and tolerability. Secondary objectives included confirmed objective response rate (Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1), progression-free survival, overall survival (OS), and PD-L1-associated clinical activity. PD-L1 positivity was defined as expression by immunohistochemistry on ≥ 5% of tumor cells. Results: Forty-four patients were treated with avelumab and followed for a median of 16.5 months (interquartile range, 15.8 to 16.7 months). The data cutoff was March 19, 2016. The most frequent treatment-related adverse events of any grade were fatigue/asthenia (31.8%), infusion-related reaction (20.5%), and nausea (11.4%). Grades 3 to 4 treatment-related adverse events occurred in three patients (6.8%) and included asthenia, AST elevation, creatine phosphokinase elevation, and decreased appetite. The confirmed objective response rate by independent central review was 18.2% (95% CI, 8.2% to 32.7%; five complete responses and three partial responses). The median duration of response was not reached (95% CI, 12.1 weeks to not estimable), and responses were ongoing in six patients (75.0%), including four of five complete responses. Seven of eight responding patients had PD-L1-positive tumors. The median progression-free survival was 11.6 weeks (95% CI, 6.1 to 17.4 weeks); the median OS was 13.7 months (95% CI, 8.5 months to not estimable), with a 12-month OS rate of 54.3% (95% CI, 37.9% to 68.1%). Conclusion: Avelumab was well tolerated and associated with durable responses and prolonged survival in patients with refractory metastatic UC.

AB - Purpose: We assessed the safety and antitumor activity of avelumab, a fully human anti-programmed death-ligand 1 (PD-L1) IgG1 antibody, in patients with refractory metastatic urothelial carcinoma. Methods: In this phase Ib, multicenter, expansion cohort, patients with urothelial carcinoma progressing after platinum-based chemotherapy and unselected for PD-L1 expression received avelumab 10 mg/kg intravenously every 2 weeks. The primary objectives were safety and tolerability. Secondary objectives included confirmed objective response rate (Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1), progression-free survival, overall survival (OS), and PD-L1-associated clinical activity. PD-L1 positivity was defined as expression by immunohistochemistry on ≥ 5% of tumor cells. Results: Forty-four patients were treated with avelumab and followed for a median of 16.5 months (interquartile range, 15.8 to 16.7 months). The data cutoff was March 19, 2016. The most frequent treatment-related adverse events of any grade were fatigue/asthenia (31.8%), infusion-related reaction (20.5%), and nausea (11.4%). Grades 3 to 4 treatment-related adverse events occurred in three patients (6.8%) and included asthenia, AST elevation, creatine phosphokinase elevation, and decreased appetite. The confirmed objective response rate by independent central review was 18.2% (95% CI, 8.2% to 32.7%; five complete responses and three partial responses). The median duration of response was not reached (95% CI, 12.1 weeks to not estimable), and responses were ongoing in six patients (75.0%), including four of five complete responses. Seven of eight responding patients had PD-L1-positive tumors. The median progression-free survival was 11.6 weeks (95% CI, 6.1 to 17.4 weeks); the median OS was 13.7 months (95% CI, 8.5 months to not estimable), with a 12-month OS rate of 54.3% (95% CI, 37.9% to 68.1%). Conclusion: Avelumab was well tolerated and associated with durable responses and prolonged survival in patients with refractory metastatic UC.

UR - http://www.scopus.com/inward/record.url?scp=85020609662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020609662&partnerID=8YFLogxK

U2 - 10.1200/JCO.2016.71.6795

DO - 10.1200/JCO.2016.71.6795

M3 - Article

C2 - 28375787

AN - SCOPUS:85020609662

VL - 35

SP - 2117

EP - 2124

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 19

ER -